MapLight Therapeutics (MPLT) Stock Price, Quote, News & History | Benzinga

MapLight Therapeutics Inc (MPLT) Stock Price, Quote, News & History

MPLTNASDAQ

Trade with Public

Trade with Public

$11.21

-0.02-0.18%

At close: Aug 21, 5:00 PM EST

$11.35

0.141.25%

After Hours: Aug 21, 5:36 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$11.35

Close

$11.21

Volume / Avg.

435.51K / 794.39K

Day Range

$11.07 - $11.61

52 Wk Range

9.10 - 40.43

Market Cap

$526.39M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

30

Short Interest

15.55%

Days to Cover

1.65

Recent MapLight Therapeutics, Inc. News

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.

Vandana Singh

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents

MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.

Vandana Singh

This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.

Avi Kapoor

This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.

Avi Kapoor

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-174.67M

Investing Cash Flow (TTM)

-250.43M

Financing Cash Flow (TTM)

463.26M

Free Cash Flow (TTM)

-175.12M

Capital Expenditure (TTM)

-453.00K

Net Change in Cash (TTM)

38.17M

Analyst Trends and Forecast

4

May

4

Jun

6

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$215.77M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.50

Earnings Yield % (TTM)

-177.74%

Earnings Yield % (FWD)

-43.86%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$7.51

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$71.63M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$11.35

Close

$11.21

Volume / Avg.

435.51K / 794.39K

Day Range

$11.07 - $11.61

52 Wk Range

9.10 - 40.43

Market Cap

$526.39M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

30

Short Interest

15.55%

Days to Cover

1.65

About

Sector

Health Care

Industry

Biotechnology

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeut...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy MapLight Therapeutics (MPLT) stock?

A

You can purchase shares of MapLight Therapeutics (NASDAQ:MPLT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are MapLight Therapeutics (MPLT) competitors?

A

Other companies in MapLight Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for MapLight Therapeutics (MPLT) stock?

A

MapLight Therapeutics has a consensus price target of $32.64.

Q

What is the current price for MapLight Therapeutics (MPLT)?

A

The stock price for MapLight Therapeutics (NASDAQ: MPLT) is $11.35 last updated August 21, 2026 at 5:36 PM EDT.

Q

Does MapLight Therapeutics (MPLT) pay a dividend?

A

There are no upcoming dividends for MapLight Therapeutics.

Q

When is MapLight Therapeutics (NASDAQ:MPLT) reporting earnings?

A

MapLight Therapeutics does not have any upcoming earnings scheduled.

Q

Is MapLight Therapeutics (MPLT) going to split?

A

There is no upcoming split for MapLight Therapeutics.

Q

What sector and industry does MapLight Therapeutics (MPLT) operate in?

A

MapLight Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.